Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy

BACKGROUND: Patients with stage II to III breast cancer have a high recurrence rate. The early detection of recurrent breast cancer remains a major unmet need. Circulating tumor DNA (ctDNA) has been proven to be a marker of disease progression in metastatic breast cancer. We aimed to evaluate the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Po-Han, Wang, Ming-Yang, Lo, Chiao, Tsai, Li-Wei, Yen, Tzu-Chun, Huang, Thomas Yoyan, Huang, Wei-Chih, Yang, Karen, Chen, Chih-Kai, Fan, Sheng-Chih, Kuo, Sung-Hsin, Huang, Chiun-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632818/
https://www.ncbi.nlm.nih.gov/pubmed/34868925
http://dx.doi.org/10.3389/fonc.2021.736769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632818/
https://www.ncbi.nlm.nih.gov/pubmed/34868925
http://dx.doi.org/10.3389/fonc.2021.736769

Ejemplares similares